Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 5, 2003, Pages 193-199

  Schmeck Lindenau, H J ^a   Naser Hijazi, B ^b   Becker, E W ^c   Henneicke von Zepelin, H H ^b   Schnitker, J ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Schaper & Brummer GmbH & Co KG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Institute for Applied Statistics   (Germany)

Author keywords

Coumarin; Hepatoxicity; Lymphocyte proliferation test

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; CETIRIZINE; COUMARIN; DOXEPIN; ERYTHROMYCIN; GAMMA GLUTAMYLTRANSFERASE; IBUPROFEN; MELILOTUS EXTRACT; OMEPRAZOLE; ROXITHROMYCIN; RUTOSIDE DERIVATIVE; SB LOT; SIMVASTATIN; TROXERUTIN;

ADULT; ALLERGIC REACTION; ARTICLE; BRONCHITIS; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXHAUSTION; FATIGUE; FEMALE; HEPATITIS; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TONSILLITIS;

EID: 0037951342     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41193     Document Type: Article

References (28)

1. Andrejak M, Gersberg M, Sgro C, Decocq G, Hamel JD, Morin M, Gras V 1998 French Pharmacovigilance Survey evaluating the hepatic toxicity of coumarin. Pharmacoepidemiol Drug Saf 7: 45-50
2. Aranda-Michel J 1998 Tests of the liver: use and misuse. Gastroenterology 6: 34-43
3. Basset ML, Dahlstrom JE 1995 Liver failure while taking coumarin. Med J Aust 163: 106
4. Beinssen APA 1994 Possible coumarin hepatotoxicity. Med J Aust 161: 725
5. Benichou C 1990 Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an International Consensus Meeting. Int J Clin Phar Ther Toxicol 28: 317-322
6. Berg AB, Becker EW 1995 The lymphocyte transformation test - a debated method for the evaluation of drug-allergic hepatic injury. J Hepatol 22: 115-118
7. Blume J, de la Haye R, Rühlmann KU 1988 Effektivität und Compliance in der Therapie chronisch-venöser Insuffizienz. CorVas 2: 89-92
8. Bourian M, Freudenstein J, Tegtmeier M, Naser-Hijazi B, Henneicke-von Zepelin HH, Legrum W 2003 Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin - additional observation of its effect on smoking (in press).
9. Bruppacher R, Rieckemann B, Naser-Hijazi B, Wüstenberg P 1998 Evaluation of the safety of a coumarin-troxerutin combination. Pharmacoepidemiol Drug Saf 7: 37-40
10. Casley-Smith JR, Morgan RG, Piller NB 1993 Treatment of lymphedema of the arms and legs with 5,6-benzo-α-pyrone. N Engl J Med 329: 1158-1163
11. Cox D, O'Kennedy R, Thornes RD 1989 The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum Toxicol 8: 501-506
12. Craxi A, Almasio P 1996 Diagnostic approach in liver enzyme elevation. J Hepatol 25: 47-51
13. Edwards IR, Biriell C 1995 Harmonization in pharmacovigilance. Drug Saf 10: 93-102
14. Faurschou P 1982 Toxic hepatitis due to benzopyrone. Hum Toxicol 1: 149-150
15. Gosh P Markin RS, Sorrell MF 1997 Coumarin-induced hepatic necrosis. AJG 92: 348-349
16. Grötz KA, Wüstenberg P, Kohnen R, Al-Nawas B, Henneicke-von Zepelin HH, Bockisch A, Kutzner J, Naser-Hijazi B, Belz GG, Wagner W 2001 Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutin in patients with head and neck cancer - a prospective, randomized, placebo-controlled, double-blind study. Br J Oral Maxill Surg 39: 34-39
17. Hoffmann J, Day U, Stammwitz U 1989 Behandlung der chronisch-venösen Insuffizienz. Fin Venentherapeutikum überzeugte doppelblind. Therapiewoche 39: 953-958
18. Johnston DE 1999 Special considerations in interpreting liver function tests. Am Fam Phys 59: 2223-2230
19. Köstering H, Bandura B, Merten HA, Wieding JU 1985 Das Verhalten der Blutgerinnung und deren Inhibitoren unter Langzeitbehandlung mit 5,6-Benzo-α-pyron (Coumarin). Arzneimittelforschung Drug Res 35: 1303-1306
20. Krajnovic P 1977 Beeinflussung infantiler Blutparameter in der Stillperiode dutch die Kombination von Coumarin und Troxerutin. Arzneimittelforschung Drug Res 27: 1499-1500
21. Lake BG 1999 Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol 37: 423-453
22. Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB, Michalal JC, Stella PJ, Levitt R, Tschetter LK, Windschitl H 1999 Lack of effect of coumarin in woman with lymphedema after treatment for breast cancer. N Engl J Med 340: 346-350
23. Morrison L, Whisby PD 1995 Side effects of coumarin. Postgrad Med J 71: 701-702
24. Piller NB 1977 An integration of the modes of action of coumarin. Arzneimittelforschung Drug Res 27: 1135-1138
25. Siegers CP, Steffen B, Weber I, Manfeldt S, Pentz R 1998 Troxerutin protects HepG2 cells against hepatotoxic response to coumarin. Naunyn-Schmiedebergs Arch Pharmacol 357: R120
26. Simic L, Pirnat L 1985 Behandlung des Ulcus cruris mit einem Benzopyron-Präparat. Inform Arzt 13: 14-20
27. Vanscheidt W, Heidrich H, Junger M, Rabe E 2000 Guidelines for testing drugs for chronic venous insufficiency. VASA 29: 274-278
28. Vanscheidt W, Rabe E, Naser-Hijazi B, Ramelet A, Partsch H, Diehm C, Shultz-Ehrenburg U, Spengel F, Wirsching M, Götz V, Schnitker J, Henneicke-von Zepelin HH 2002 The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency (CVI): a double-blind, placebo-controlled, randomized study. VASA 31: 185-190